Company: HCWB
Filing Date: 2025-07-01
Form Type: 8-K
Source: 0000950170-25-091891
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-07-01
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

As reported in our Current Report on Form 8-K filed on May 15, 2025, HCW Biologics Inc. (the “ Company”) entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. (“ Armistice”) on May 13, 2025 that included a grant of pre-funded warrants to purchase up to 513,140 shares of the Company’s common stock with par value of $0.0001 per share (“ Common Stock”) that may be exercised at any time at an exercise price of $0.0001 per share (the “ Pre-Funded Warrants”). As previously reported by the Company, Armistice exercised Pre-Funded Warrants to purchase an aggregate of 459,140 shares of Common Stock. On June 18, 2025, Armistice exercised Pre-Funded Warrants to purchase 54,000 shares of Common Stock. With this exercise, the Pre-Funded Warrants have been fully exercised with none left outstanding.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                        HCW BIOLOGICS INC.                                 
  Date:      July 1, 2025      By:      /s/ Hing C. Wong                                   
                                        Hing C. Wong, Founder and Chief Executive Officer